Skip to content

Cell Free Preimplantation Genetic Testing

Evaluation of Cell Free Preimplantation Genetic Testing

Status
Not yet recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04628507
Enrollment
200
Registered
2020-11-13
Start date
2026-06-11
Completion date
2027-12-11
Last updated
2025-08-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Infertility, Female, Infertility, Male

Keywords

PGT, Noninvasive

Brief summary

This study aims to develop preimplantation genetic testing methods from embryo culture media (cell free). Genetic testing of culture media will be compared to conventional methods based on embryo biopsies.

Detailed description

Consenting patients will receive standard clinical IVF and PGT. Culture media from embryos will be collected for analysis. Collection of media will include laser assisted collapse of the blastocyst on day 5, 6, or 7 in order to release blastocoel fluid into the culture media. Embryos diagnosed as aneuploid or monogenic disorder affected (abnormal embryos) will be donated for additional analysis with patient consent. Results obtained from culture media will not be provided to the patients. The information obtained from cf-PGT will be compared to results obtained from embryo biopsies obtained as part of routine PGT and evaluated for concordance and reliability. Abnormal embryos will be rebiopsied (\ 3 to 4 times) to evaluate concordance with cf-PGT and the original clinical trophectoderm biopsy PGT results. All cases will be labelled using a 5-digit barcode and embryo number or saliva source code. Because PGT will be conducted under clinical regulatory approval (CAP and CLIA), patient information will be protected under HIPAA guidelines, including sending reports in encrypted secure email per standard operating procedures. All publications and presentations will maintain de-identification of any patient data used. Patients may withdraw from the study at any time by contacting the principal investigator of their respective recruiting site. They will continue to receive standard of care through their treating IVF center. A recruitment target of 200 patients is intended for this study.

Interventions

OTHERSpent media collection

Embryo spent culture media, otherwise discarded as per standard of care, is collected once embryos have completed in vitro culture.

Sponsors

Genomic Prediction Inc.
Lead SponsorINDUSTRY

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Healthy volunteers
Yes

Inclusion criteria

* Patients undergoing IVF electing to utilize LifeView testing (PGT) will be offered participation in this study.

Exclusion criteria

* None

Design outcomes

Primary

MeasureTime frameDescription
Concordance with PGT14 dyasConcordance rates with PGT diagnosis from trophectoderm biopsies

Countries

United States

Contacts

Primary ContactTalia Metzgar, RN
Talia@genomicprediction.com9735294223

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026